Report on bronchitis;Argumentaire bronchites

Medecine et Maladies Infectieuses

Volumn 31, Issue 5, 2001, Pages 302-338

  Chidiac, C ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CEFUROXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; MACROLIDE; MINOCYCLINE; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL SUPERINFECTION; BRONCHITIS; CONFERENCE PAPER; DISEASE EXACERBATION; PATHOPHYSIOLOGY; PNEUMONIA; RESPIRATORY TRACT INFECTION;

EID: 0034968959     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(01)00204-9     Document Type: Conference Paper

References (156)

1. Diagnosis of acute bronchitis in adults: A national survey of famili physicians
2. Acute bronchitis: Results of US and european trials of antibiotic therapy
3. Acute bronchitis: Aetiology, symptoms and treatment
4. A study of clinical features and treatment of acute bronchitis by Japanese primary care physicians
5. Role of intracellular pathogens in respiratory tract infections
6. Evidence that Chlamydia pneumoniae causes pneumoniae and bronchitis
7. Chlamydia pneumoniae pneumonia in hospitalized patients
8. Chlamydia pneumonia (TWAR): A common aget in acute bronchitis
9. Pulmonary function in uncomplicated influenza
10. Changes in pulmonary function after naturally acquired respiratory infection in normal persons
11. Acute bronchitis in the community: Clinical features, infective factors, changes in pulmonary function and bronchial reactivity to histamine
12. Reversible airflow limitation in adults with respiratory infection
13. ème conférence de consensus en thérapeutique anti-infectieuse de la Société de Pathologic Infectieuse de Langue Française, Lille - 18 octobre 1991
14. Acute bronchitis in adults. How close do we come to its aetiology in general practice
15. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community
16. Acute viral infections of upper respiratory tract in elderly people living in the community: Comparative, prospective, population based study of disease burden
17. Epidémiologie des infections respiratoires basses aiguës de l'adulte. Rôle de Chlamydia pneumonie et de Mycoplasma pneumoniae
18. Evidence that Chlamydia pneumomue causes pneumoniae and bronchitis
19. Outbreak of pneumonia in a long-term care facility: Antecedent human parainfluenza virus l'infection may predispose to bacterial pneumonia
20. Prospective case-control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary care
21. Antibiothérapie par voie générate en pratique courante: Infections ORL et respiratoires basses
22. Decreasing antibiotic use in ambulatory practice
23. Randomized placebo-controlled trials of antibiotics for acute bronchitis: A critical review of the literature
24. Treatment of acute bronchitis in adults without underlying lung disease
25. Effects of doxycycline in patients with acute cough and purulent sputum: A double blind placebo controlled trial
26. Effectiveness of erythromycin in the treatment of acute bronchitis
27. The place of antimicrobial chemotherapy in the treatment of adults with acute bronchitis: A double-blind placebo-controlled trail
28. Quantitative systematic review of randomised controlled trials comparing antibiotics with placebo for acute cough in adults
29. Are antibiotics effective treatment for acute bronchitis? A meta-analysis
30. Antibiotics in acute bronchitis: A meta-analysis
31. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection
32. Azithromycin compared with ciarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: A cost of illness study
33. A multicentre study comparing the safety and efficacy of dirithromycin with erythromycin in the tratment of bronchitis
34. Comparison of azithromycin ans co-amoxiclav in the treatment of acute bronchitid and acute exacerbations of chronic bronchitis in adults
35. Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections
36. Etude randomisée en parallèle et en double insu de la minocycline 100 mg (Minocyne®) vs roxithromycine 300 mg (Rulid®), dans le traitement des bronchites aiguës saisonnières, en pratique de ville
37. Clarithromycin versus cefaclor in low respiratory tract infections
38. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis
39. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis
40. Clarithromycin in the treatment of respiratory tract infections
41. La stratégie antibiotique dans les infections bronchiques
42. Antibiotics: Neither cost effective nor cough effective
43. Treatment of acute bronchitis in adults. A national survey of family physicians
44. Factors associated with antibiotic use for acute bronchitis
45. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians
46. Antibiotics for acute bronchitis: A meta-analysis
47. Antibiotics: Neither cost effective nor 'cough' effective
48. Antibiotics in acute bronchitis and exacerbations of chronic bronchitis: What is general practitioners' habit?
49. What will it take to stop physicians from prescribing antibiotics in acute bronchitis?
50. Evaluation and treatment of respiratory infections: Does managed care make a difference?
51. The effect of reimbursement on the use of antibiotics
52. Societe de pneumologie de langue francaise, Recommandations pour la prise en charge des BPCO
53. ERS Consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease
54. Conduite a tenir devant une infection respiratoire basse communautaire de l'adulte
55. Definition, epidemiology, pathophysiology diagnosis and staging of COPD
56. Guide lines for the management of chronic obstructive pulmonary disease
57. Recommandations on the management of chronic bronchitis
58. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
59. Recommandations pour la prise en charge anti-infectieuse des exacerbations de bronchite chronique
60. Acute exacerbations of chronic bronchitis
61. Epidemiology and treatment of chronic bronchitis and its exacerbations
62. Bacterial infection in chronic obstructive pulmonary disease
63. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function
64. Bacterial infection in chronic obstructive pulmonary disease
65. Characterization of distral bronchial microflora during acute exacerbation of chronic bronchitis
66. Prospective case control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary case
67. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis
68. Acute exacerbations of chronic bronchitis: An international comparison
69. Efficacy of oral Ciprofloxacin vs Clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
70. Randomized, double blind study of ciprofloxacin and Cefuroxime axetil for treatment of acute haclerial exacerbations of chronic bronchitis
71. Etiology, susceptibility and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg BID versus Clarithromycin 500 mg BID
72. A 1 year community based health economic study of Ciprofloxacin versus usual antibiotic treatment in acute exacerbations of chronic bronchitis
73. Lower respiratory tract infection therapy: The role of Ciprofloxacin
74. Efficacy and safety of 10 day course of 400 or 600 mg of Grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10 day course of 500 mg of Ciprofloxacin twice daily
75. Levofloxacin versus Cefuroxime Axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double blind study
76. Trovatloxacin versus Amoxicilline/Clavulanic acid in the treatment of acute exacerbations of chronic bronchitis
77. Randomized, double blind study of Grepafloxacin versus Amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis
78. Treatment of acute exacerbations of chronic bronchitis: Comparison of Trovafloxacin and Amoxycillin in a multicentre, double blind double dummy study
79. Comparative safety and efficacy of Sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double blind, randomized, parallel, multicentre study
80. Sparfloxacin versus Ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis
81. Safety and efficacy of oral Levotloxacin versus Cefuroxime Axetil in acute bacterial exacerbations of chronic bronchitis
82. Multicenter randomized study comparing efficacy and safety of oral Levofloxacin and Cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis
83. Levotloxacin and Sparfloxacin
84. Safety and efficacy of Clarithromycin versus Cefuroxime Axetil in the treatment of acute bacterial exacerbation of chronic bronchitis
85. Comparative safety and efficacy of Clarithromycin and Ampicillin in the treatment of out patients with acute bacterial exacerbation of chronic bronchitis
86. Clarithromycin versus Cefaclor for the treatment of mild to moderate acute bacterial bronchitis
87. Comparaison de I'efficacite et de la tolerance de la Clarithromycine et du Cefpodoxime proxetil dans le traitement des surinfections aiguës des bronchopneumopathes chroniques obstructifs
88. Double blind, randomized study comparing the efficacies and safeties of a short (3-day) course of Azithromycin and a 5 day course of Amoxicillin in patients with acute exacerbation of chronic bronchitis
89. Efficacy and tolerability of Azithromycin versus Roxithromycin in the treatment of acute lower respiratory tract infections
90. A short (3 day) course of Azithromycin tablets versus a 10 day course of Amoxicillin - Clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long term outcome
91. Efficacy and tolerability of Azithromycin versus Amoxicillin - Clavulanic and in acute purulent exacerbation of chronic bronchitis
92. Clinical efficacy of dirithromycine in acute exacerbations of chronic bronchitis
93. Dirithromycin versus Amoxiclav in the treatment of acute exacerbations of chronic bronchitis
94. Five day Dirithromycin therapy is as effective as seven day Erythromycin therapy for acute exacerbations of chronic bronchitis
95. A comparison of 5 days of Dirithromycin and 7 days of Clarithromycin in acute bacterial exacerbation of chronic bronchitis
96. A comparison of 5 days of Dirithromycin and 7 days of Roxithromycin in acute bacterial exacerbation of chronic bronchitis
97. Bronchite aiguë et surinfection de bronchite chronique. L'Azithromycine, son efficacité en situation quotidienne
98. Clinical efficacy of Roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to H. influenzae. A meta-analysis
99. Sequential therapy with Cefuroxime followed by Cefuroxime Axetil in acute exacerbations of chronic bronchitis
100. Short course Cefuroxime Axetil therapy in the treatment of acute exacerbations of chronic bronchitis
101. Comparison of the efficacy and safety of a short course of Ceftibuten with that of Amoxicilline/Clavulanate in the treatment of acute exacerbation of chronic bronchitis
102. Comparison of Ceftibuten versus Amoxicllin/Clavulanate in the treatment of acute exacerbations of chronic bronchitis
103. A comparison of Cefpodoxime proxetil and Cefaclor in the treatment of acute exacerbation of COPD in adults
104. Comparison of Ceftibuten once daily and Amoxicillin/Clavulanate 3 times daily in the acute exacerbations of chronic bronchitis
105. Randomized comparison of once daily Ceftibuten and twice daily Clarithromycin in the treatment of acute exacerbation of chronic bronchitis
106. Traitement des exacerbations de bronchites chroniques : Cefuroxime IM avec relais per os par Cefuroxime Axetil versus Ceftriaxone
107. Successful treatment of respiratory tract infections in patients with chronic respiratory disease. How to make objective conclusions?
108. Clinical studies in chronic bronchitis: A need for better definition and classification of severity
109. The infection free interval: Its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis
110. Is an objective assessment of antibiotic therapy in exacerbation of chronic bronchitis possible
111. Infectious exacerbations of chronic bronchitis: Diagnosis and management
112. Acute exacerbations of chronic bronchitis
113. Increased incidence of Ciprofloxacin resistance in Penicillin resistant pneumococcie in Northern Ireland
114. Decreased susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
115. Emergence of Fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
116. Low dosage and long treatment duration of β-lactam: Risk factors for the carriage of Penicillin resistant Streptococcus pneumoniae
117. Penicillin resistant Streptococcus pneumoniae: Selection by both β-lactam and non β-lactam antibiotics
118. Prescription et consommation des antibiotiques en ambulatoire
119. Infections respiratoires recidivantes du sujet atteint de bronchite chronique obstructive : Prise en charge medicale et couts
120. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis
121. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service
122. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. ATS Statement
123. ERS - Consensus Statement. Optimal assessment management of chronic obstructive pulmonary disease (COPD)
124. Societe de Pneumologie de Langue Francaise, Recommandations pour la prise en charge des bronchopneumopathies chroniques obstructives
125. BTS Guidelines for the management of chronic obstructive pulmonary disease
126. Current issues in the management of chronic obstructive pulmonary diseases
127. Management of acute exacerbation of chronic obstructive pulmonary disease
128. When can an exacerbation of COPD be treated at home?
129. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease
130. Bronchodilator responses to anticholinergic and bêta-adrenergic agents in acute and stable COPD
131. Pharmacoeconomic evaluation of a combination of ipratropium + albuterol compared with Ipratropium alone and albuterol in COPD
132. What role for theophylline therapy?
133. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation
134. Are inhaled Glucocorticosteroids Effective in Chronic Obstructive Pulmonary Disease?
135. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
136. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease
137. Long term effect of inhaled budesonide in mild an moderate chronic obstructive pulmonary disease: A randomised controlled trial
138. N-Acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD
139. Nisobutyrylcysteïne a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis
140. Nebulized versus intravenous albuterol in hypercapnic acute asthma
141. Nebulisers for chronic obstructive pulmonary disease
142. Apport de la nebulisation dans les exacerbations des bronchopneumopathies chroniques obstructives : Place des anticholinergiques
143. Can we justify Ipratropium therapy as initial management of acute exacerbations of COPD?
144. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease
145. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease
146. Oral corticosteroïds in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial